Cynapsus
Toronto, CA · 1 known investors
Cynapsus is a specialty central nervous system pharmaceutical company developing a fast-acting, sublingual thin film for on-demand management of OFF episodes in Parkinson's disease patients. It is preparing to commercialize the therapy.
Founders & leadership
MN
Margaret Nan HutchinsonNamed on SEC filing
AW
Andrew WilliamsNamed on SEC filing
AG
Anthony GiovinazzoNamed on SEC filing
TB
Thierry BilbaultNamed on SEC filing
TD
Tamar D. HowsonNamed on SEC filing
RH
Ronald HoskingNamed on SEC filing
RS
Rochelle StenzlerNamed on SEC filing
IO
Ilan OrenNamed on SEC filing
TG
Tomer GoldNamed on SEC filing
PM
Perry MolinoffNamed on SEC filing
NB
Nathan BrysonNamed on SEC filing
AT
Alan TorrieNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$32.2M disclosed across 3 rounds · 2011–2015
▶$16.8MraisedApr 2015 · 14 investors · PharmaceuticalsRule 506(b)
▶$16.8MraisedApr 2015 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Margaret Nan HutchinsonDirector
- Andrew WilliamsExecutive Officer
- Anthony GiovinazzoExecutive Officer, Director
- Thierry BilbaultExecutive Officer
- Tamar D. HowsonDirector
- Ronald HoskingDirector
- Rochelle StenzlerDirector
- Ilan OrenDirector
- Tomer GoldDirector
- Perry MolinoffDirector
- Offering amount
- $16.8M
- Amount sold
- $16.8M
- Sales commissions
- $1M
- Placement agents
- Noble Financial Capital Markets
- First sale
- Mar 2015
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$14.5MraisedApr 2014 · 19 investors · PharmaceuticalsRule 506(b)
▶$14.5MraisedApr 2014 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Perry MolinoffDirector
- Nan HutchinsonDirector
- Anthony GiovinazzoExecutive Officer, Director
- Rochelle StenzlerDirector
- Alan D. C. RyleyDirector
- Tomer GoldDirector
- Ilan OrenDirector
- Andrew WilliamsExecutive Officer
- Ronald HoskingDirector
- Offering amount
- $42.9M
- Amount sold
- $14.5M
- Sales commissions
- $1M
- Placement agents
- Brookline Group, LLC, Noble Financial Capital Markets
- First sale
- Apr 2014
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$939.5KraisedMar 2012 · 7 investors · PharmaceuticalsRule 506(b)
▶$939.5KraisedMar 2012 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nathan BrysonExecutive Officer
- Anthony GiovinazzoExecutive Officer
- Alan TorrieDirector
- David HillDirector
- Ronald HoskingDirector
- Julia LevyDirector
- Andrew WilliamsExecutive Officer
- Alan RyleyDirector
- Rochelle StenzlerDirector
- Offering amount
- $939.5K
- Amount sold
- $939.5K
- Sales commissions
- $38.3K
- Placement agents
- Summer Street Research Partners
- First sale
- Sep 2011
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Cynapsus do?
- Cynapsus is a specialty central nervous system pharmaceutical company developing a fast-acting, sublingual thin film for on-demand management of OFF episodes in Parkinson's disease patients. It is preparing to commercialize the therapy.
- Who are Cynapsus's investors?
- Cynapsus's investors include Aisling Capital.
- How much funding has Cynapsus raised?
- Cynapsus has disclosed $32.2M raised across 3 rounds.
- Where is Cynapsus headquartered?
- Cynapsus is headquartered in Toronto, CA.